Skip to main content
. Author manuscript; available in PMC: 2016 Mar 13.
Published in final edited form as: ACS Infect Dis. 2015 Jan 21;1(3):140–148. doi: 10.1021/id5000458

Table 2.

ML283 Analogue with Optimal Antiviral Activity in Cells

graphic file with name nihms689963u3.jpg
compd (CID) DENV ATPase IC50a (μM) DENV helicase IC50a (μM) replicon EC50b (μM) TIc
24 (49849289) 0.5 ± 0.1 1.5 ± 0.2 7.1±3 17
a

As defined in Table 1.

b

Half-maximal inhibitory concentration observed in assays monitoring BHK cell DENV replicon content.

c

Half-maximal inhibitory concentration observed in BHK cell viability assays (CC50)/replicon EC50.